8 citations
,
April 1988 in “Journal of endocrinological investigation” This study found that topically administered spironolactone in healthy volunteers resulted in no detectable systemic absorption or changes in related hormone levels over 72 hours, indicating local effect only.
November 2024 in “International Medical Case Reports Journal” Glucocorticoid treatment in lupus can cause oral lesions, which need early diagnosis and comprehensive care.
January 2018 in “Springer eBooks” This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.
1 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” This report describes cases of transient thyrotoxicosis potentially linked to oral retinoid treatment, suggesting a possible mechanism involving increased iodine uptake by thyroid cells.
15 citations
,
September 2021 in “Journal of Clinical Medicine” This study observed that in children who unintentionally consumed high-dose oral minoxidil, 65% developed hypertrichosis, predominantly on the face, and 15% experienced mild systemic side effects.
97 citations
,
January 2006 in “Dermatology” This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.
January 2007 in “Yearbook of Dermatology and Dermatologic Surgery” Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.
39 citations
,
October 2014 in “Schweizerische medizinische Wochenschrift” This study found that while cyclophosphamide remains effective for severe autoimmune conditions, it is associated with gastrointestinal side effects, infections, some cases of irreversible amenorrhoea, and a higher risk of malignancies, emphasizing the need for long-term monitoring.
2 citations
,
October 2016 This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.
PRP hair treatment is generally safe but may cause minor pain, bleeding, redness, and scalp tightness, and isn't suitable for everyone.
50 citations
,
July 2014 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.
9 citations
,
April 2021 in “Climacteric” This study provides a guideline for the safe and effective use of testosterone in women with hypoactive sexual desire disorder, recommending systemic transdermal testosterone for appropriate candidates while highlighting the importance of informed consent and monitoring due to unestablished long-term safety.
7 citations
,
November 2021 in “Anais Brasileiros de Dermatologia” This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.
20 citations
,
April 2021 in “Journal of Womens Health” This guideline provides evidence-based recommendations for prescribing testosterone therapy to women with hypoactive sexual desire disorder, noting a moderate therapeutic benefit but highlighting limited data and regulatory challenges.
30 citations
,
April 2021 in “The Journal of Sexual Medicine” This guideline provides recommendations for prescribing systemic testosterone to women with hypoactive sexual desire disorder, emphasizing safe dosing, monitoring, and the need for informed consent despite regulatory challenges.
11 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This letter highlights that levonorgestrel intrauterine devices may lead to fewer systemic side effects, like acne, compared to its oral administration due to lower systemic levels of progestogens.
In this case study, a 12-year-old boy with alopecia totalis experienced hair regrowth on the side of his scalp treated with a combination of systemic steroids and dithranol, suggesting a potential synergistic effect that may help manage severe alopecia areata with minimal side effects.
July 2024 in “Skin Appendage Disorders” In this study, researchers found that low-dose oral minoxidil for androgenetic alopecia in men generally showed a good safety profile, with hypertrichosis being the most frequent side effect, while systemic side effects like dizziness and hypotension were less common and no life-threatening effects were observed.
In this study, PRP combined with systemic therapy for androgenetic alopecia showed higher, but not statistically significant, improvements in hair density and width compared to PRP alone, with no increase in side effects; further prospective studies are recommended.
January 2025 in “Hospital Pharmacology - International Multidisciplinary Journal” In this study, researchers explored the effects of various medications on eye health, noting that systemic and local ophthalmic drugs can lead to both widespread and specific ocular side effects, with serious adverse events most associated with neurotropic, immunotropic, and antitumor medications.
January 2025 in “Journal of Drugs in Dermatology” This study found that oral minoxidil is superior to topical minoxidil in terms of ease of use, adherence, and patient satisfaction, without increasing systemic side effects, although it did have a higher incidence of hypertrichosis.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
146 citations
,
July 2003 in “Journal of the American Academy of Dermatology” In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.
122 citations
,
March 2013 in “Expert opinion on drug delivery” This review summarizes drug delivery strategies to hair follicles, highlighting physicochemical factors affecting penetration and the use of stimuli-responsive particulate carriers, but reports no new clinical findings.
52 citations
,
February 1985 in “Archives of Dermatology” Minoxidil absorbs poorly through skin, with low risk of side effects at 1-2% concentration.
42 citations
,
January 2007 in “Pediatric dermatology” This report describes an 11-year-old boy with Netherton syndrome who developed Cushing syndrome after using low-potency hydrocortisone ointment extensively, highlighting caution with long-term topical treatments in such conditions.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.
1 citations
,
November 2024 in “JAAD reviews.” This study reviewed literature on patient preferences for severe alopecia areata treatment, finding diverse tolerance for risks like infections and cancer in exchange for effectiveness. Patients favored safe, convenient, and effective topical treatments and valued shared decision-making with healthcare providers.
This research indicates that topical minoxidil seems to be the safest option for treating hair loss in dialysis patients, but caution is advised with oral treatments like low-dose minoxidil due to potential systemic side effects.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study found that topical minoxidil is potentially the safest hair loss treatment for dialysis patients, while caution is advised for oral treatments like low-dose minoxidil due to possible systemic side effects.